Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Osteopontin (OPN) has been associated with enhanced malignancy in breast cancer, but its functional role in this disease is poorly understood.
|
10435636 |
1999 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Osteopontin (OPN) is a secreted glycophosphoprotein which induces migration of mammary carcinoma cells, and has been implicated in the malignancy of breast carcinoma.
|
10861844 |
2000 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Osteopontin expression is related to urinary stone formation and several diseases associated with calcification such as atherosclerosis, breast cancer, and meningioma.
|
12142743 |
2002 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Osteopontin (OPN) is a secreted, integrin-binding glycophosphoprotein that has been implicated in breast cancer.
|
12606946 |
2003 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Osteopontin induction of hyaluronan synthase 2 expression promotes breast cancer malignancy.
|
16807238 |
2006 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Osteopontin that associates with metabolism of calcium is one of the important factors in the development and prognosis of human breast cancer.
|
17089001 |
2006 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
OPN expression profiles are significantly associated with tumour grade, stage and patient prognosis in breast cancer.
|
19192668 |
2009 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Osteopontin expression has been associated with breast cancer progression, regardless of the histological subtype of the cancer.
|
23900428 |
2013 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Osteopontin Regulates VEGFA and ICAM-1 mRNA Expression in Breast Carcinoma.
|
25972323 |
2015 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
OPN and MMPs play a role in cancer development and are prognostic markers in breast cancer progression.
|
26482249 |
2015 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Osteopontin splice variants are differential predictors of breast cancer treatment responses.
|
27400751 |
2016 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
OPN mRNA expression was significantly associated with age (60.9% in high OPN tumors vs. 54.1% in low OPN tumors, p = 0.047), ER/PgR-negative status (25.7 vs. 17.2%, p = 0.004) and BC subtypes (p = 0.021).
|
28193231 |
2017 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
OPN thus is a promising predictive biomarker for anti-EGFR therapy in breast cancer.
|
30025479 |
2018 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Aerosol-delivered small hairpin osteopontin blocked breast cancer metastasis.
|
21203518 |
2010 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Although basal transcription repression was impaired and the pro-metastatic protein osteopontin was differentially down-regulated by BRMS1(L174D) and BRMS1(DeltaCC1), both down-regulated the epidermal growth factor receptor and suppressed metastasis in MDA-MB-231 and -435 breast cancer xenograft models.
|
18211900 |
2008 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Because the secreted metastasis mediator Osteopontin (OPN) is a marker for breast cancer aggressiveness, its presence in these lesions may reflect progression risk.
|
30353046 |
2018 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Bone sialoprotein (BSP) and osteopontin (OPN) are important factors in the metastasis of breast cancer, which were examined as targets for antineoplastic therapy by siRNA.
|
22407340 |
2012 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Collectively, our results show that OPN transcripts have no distinct role in breast cancer formation in vivo.
|
23416968 |
2013 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Contrasting expression of thrombospondin-1 and osteopontin correlates with absence or presence of metastatic phenotype in an isogenic model of spontaneous human breast cancer metastasis.
|
11801541 |
2002 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Deletion of the thrombin cleavage domain of osteopontin mediates breast cancer cell adhesion, proteolytic activity, tumorgenicity, and metastasis.
|
21247495 |
2011 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Despite its abundance in carcinomas, BSP expression was not detected in a panel of 11 human breast cancer cell lines (MCF-7, T47D, SK-Br-3, MDA-MB-453, MDA-MB-231, MDA-MB-436, BT549, MCF-7ADR, Hs578T, MDA-MB-435, and LCC15-MB) and OPN expression was detected only in two of these (MDA-MB-435 and LCC15-MB).
|
10418827 |
1999 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Determination of OPN mRNA expression can be expected to be a guide to clinical therapy and prediction of the prognosis of breast cancer patients.
|
23244138 |
2012 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Down-regulation of osteopontin expression by RNA interference affects cell proliferation and chemotherapy sensitivity of breast cancer MDA-MB-231 cells.
|
22143930 |
2012 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Elevated expression of OPN and TSP-1 may play a role in the pathogenesis of breast cancer.
|
12927044 |
2003 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Elevated expression of HIF1α and OPN was observed in pre-neoplastic and early stage infiltrating ductal carcinoma implicating the role of these proteins in neoplastic progression of breast cancer.
|
23728336 |
2014 |